Jeong Soocheol, Aikata Hiroshi, Katamura Yoshio, Azakami Takahiro, Kawaoka Tomokazu, Saneto Hiromi, Uka Kiminori, Mori Nami, Takaki Shintaro, Kodama Hideaki, Waki Koji, Imamura Michio, Shirakawa Hiroo, Kawakami Yoshiiku, Takahashi Shoichi, Chayama Kazuaki
Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3, Kasumi, Hiroshima, Japan.
World J Gastroenterol. 2007 Oct 21;13(39):5188-95. doi: 10.3748/wjg.v13.i39.5188.
To assess the efficacy of low-dose intermittent interferon (IFN) therapy in patients with hepatitis C virus (HCV)-related compensated cirrhosis who had received curative treatment for primary hepatocellular carcinoma (HCC).
We performed a prospective case controlled study. Sixteen patients received 3 MIU of natural IFN-alpha intramuscularly 3 times weekly for at least 48 wk (IFN group). They were compared with 16 matched historical controls (non-IFN group).
The cumulative rate of first recurrence of HCC was not significantly different between the IFN group and the non-IFN group (0% vs 6.7% and 68.6% vs 80% at 1- and 3-year, P = 0.157, respectively). The cumulative rate of second recurrence was not also significantly different between the IFN group and the non-IFN group (0% vs 6.7% and 35.9% vs 67% at 1- and 3-year, P = 0.056, respectively). Although the difference in the Child-Pugh classification score between the groups at initial treatment of HCC was not significant, the score was significantly worse at the time of data analysis in the non-IFN group than IFN group (7.19 +/- 1.42 vs 5.81 +/- 0.75, P = 0.0008). The cumulative rate of deviation from objects of any treatment for recurrent HCC was also higher in the non-IFN group than IFN group (6.7% and 27% vs 0 and 0% at 1- and 3-year, P = 0.048, respectively).
Low-dose intermittent IFN-alpha therapy for patients with HCV-related compensated cirrhosis after curative HCC treatment was effective by making patients tolerant to medical or surgical treatment for recurrent HCC in the later period of observation.
评估低剂量间歇干扰素（IFN）疗法对接受过原发性肝细胞癌（HCC）根治性治疗的丙型肝炎病毒（HCV）相关代偿期肝硬化患者的疗效。
我们进行了一项前瞻性病例对照研究。16例患者每周3次肌肉注射3百万国际单位天然α干扰素，持续至少48周（IFN组）。将他们与16例匹配的历史对照（非IFN组）进行比较。
IFN组和非IFN组HCC首次复发的累积率无显著差异（1年时分别为0%对6.7%，3年时分别为68.6%对80%，P = 0.157）。IFN组和非IFN组第二次复发的累积率也无显著差异（1年时分别为0%对6.7%，3年时分别为35.9%对67%，P = 0.056）。虽然在HCC初始治疗时两组间Child-Pugh分级评分差异不显著，但在数据分析时非IFN组的评分显著差于IFN组（7.19±1.42对5.81±0.75，P = 0.0008）。非IFN组复发性HCC任何治疗目标偏离的累积率也高于IFN组（1年时分别为6.7%和27%对0和0%，3年时分别为6.7%和27%对0和0%，P = 0.048）。
对接受过HCC根治性治疗的HCV相关代偿期肝硬化患者，低剂量间歇α干扰素疗法有效，可使患者在观察后期耐受复发性HCC的药物或手术治疗。
